318 related articles for article (PubMed ID: 23601496)
21. HLA- and genotype-based risk assessment model to identify infantile onset pompe disease patients at high-risk of developing significant anti-drug antibodies (ADA).
De Groot AS; Kazi ZB; Martin RF; Terry FE; Desai AK; Martin WD; Kishnani PS
Clin Immunol; 2019 Mar; 200():66-70. PubMed ID: 30711607
[TBL] [Abstract][Full Text] [Related]
22. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa.
de Vries JM; van der Beek NA; Kroos MA; Ozkan L; van Doorn PA; Richards SM; Sung CC; Brugma JD; Zandbergen AA; van der Ploeg AT; Reuser AJ
Mol Genet Metab; 2010 Dec; 101(4):338-45. PubMed ID: 20826098
[TBL] [Abstract][Full Text] [Related]
23. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.
Kishnani PS; Goldenberg PC; DeArmey SL; Heller J; Benjamin D; Young S; Bali D; Smith SA; Li JS; Mandel H; Koeberl D; Rosenberg A; Chen YT
Mol Genet Metab; 2010 Jan; 99(1):26-33. PubMed ID: 19775921
[TBL] [Abstract][Full Text] [Related]
24. Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease.
Zhang P; Sun B; Osada T; Rodriguiz R; Yang XY; Luo X; Kemper AR; Clay TM; Koeberl DD
Hum Gene Ther; 2012 May; 23(5):460-72. PubMed ID: 22260439
[TBL] [Abstract][Full Text] [Related]
25. Atypical immunologic response in a patient with CRIM-negative Pompe disease.
Abbott MA; Prater SN; Banugaria SG; Richards SM; Young SP; Rosenberg AS; Kishnani PS
Mol Genet Metab; 2011 Dec; 104(4):583-6. PubMed ID: 21889385
[TBL] [Abstract][Full Text] [Related]
26. Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via newborn screening: the benefits of early treatment with enzyme replacement therapy and immune tolerance induction.
Li C; Desai AK; Gupta P; Dempsey K; Bhambhani V; Hopkin RJ; Ficicioglu C; Tanpaiboon P; Craigen WJ; Rosenberg AS; Kishnani PS
Genet Med; 2021 May; 23(5):845-855. PubMed ID: 33495531
[TBL] [Abstract][Full Text] [Related]
27. Early higher dosage of alglucosidase alpha in classic Pompe disease.
Spada M; Pagliardini V; Ricci F; Biamino E; Mongini T; Porta F
J Pediatr Endocrinol Metab; 2018 Dec; 31(12):1343-1347. PubMed ID: 30433875
[TBL] [Abstract][Full Text] [Related]
28. Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients.
Masat E; Laforêt P; De Antonio M; Corre G; Perniconi B; Taouagh N; Mariampillai K; Amelin D; Mauhin W; Hogrel JY; Caillaud C; Ronzitti G; Puzzo F; Kuranda K; Colella P; Mallone R; Benveniste O; Mingozzi F;
Sci Rep; 2016 Nov; 6():36182. PubMed ID: 27812025
[TBL] [Abstract][Full Text] [Related]
29. Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy.
Prater SN; Patel TT; Buckley AF; Mandel H; Vlodavski E; Banugaria SG; Feeney EJ; Raben N; Kishnani PS
Orphanet J Rare Dis; 2013 Jun; 8():90. PubMed ID: 23787031
[TBL] [Abstract][Full Text] [Related]
30. Use of cardiac magnetic resonance imaging to evaluate cardiac structure, function and fibrosis in children with infantile Pompe disease on enzyme replacement therapy.
Barker PC; Pasquali SK; Darty S; Ing RJ; Li JS; Kim RJ; DeArmey S; Kishnani PS; Campbell MJ
Mol Genet Metab; 2010 Dec; 101(4):332-7. PubMed ID: 20875764
[TBL] [Abstract][Full Text] [Related]
31. Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy.
Parini R; De Lorenzo P; Dardis A; Burlina A; Cassio A; Cavarzere P; Concolino D; Della Casa R; Deodato F; Donati MA; Fiumara A; Gasperini S; Menni F; Pagliardini V; Sacchini M; Spada M; Taurisano R; Valsecchi MG; Di Rocco M; Bembi B
Orphanet J Rare Dis; 2018 Feb; 13(1):32. PubMed ID: 29422078
[TBL] [Abstract][Full Text] [Related]
32. The earliest enzyme replacement for infantile-onset Pompe disease in Japan.
Tocan V; Mushimoto Y; Kojima-Ishii K; Matsuda A; Toda N; Toyomura D; Hirata Y; Sanefuji M; Sawada T; Sakai Y; Nakamura K; Ohga S
Pediatr Int; 2022 Jan; 64(1):e15286. PubMed ID: 36074069
[TBL] [Abstract][Full Text] [Related]
33. The potential impact of timing of IVIG administration on the efficacy of rituximab for immune tolerance induction for patients with Pompe disease.
Desai AK; Rosenberg AS; Kishnani PS
Clin Immunol; 2020 Oct; 219():108541. PubMed ID: 32681978
[TBL] [Abstract][Full Text] [Related]
34. Mapping the T helper cell response to acid α-glucosidase in Pompe mice.
Nayak S; Sivakumar R; Cao O; Daniell H; Byrne BJ; Herzog RW
Mol Genet Metab; 2012 Jun; 106(2):189-95. PubMed ID: 22494547
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.
Case LE; Bjartmar C; Morgan C; Casey R; Charrow J; Clancy JP; Dasouki M; DeArmey S; Nedd K; Nevins M; Peters H; Phillips D; Spigelman Z; Tifft C; Kishnani PS
Neuromuscul Disord; 2015 Apr; 25(4):321-32. PubMed ID: 25617983
[TBL] [Abstract][Full Text] [Related]
36. Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model.
Joseph A; Munroe K; Housman M; Garman R; Richards S
Clin Exp Immunol; 2008 Apr; 152(1):138-46. PubMed ID: 18307520
[TBL] [Abstract][Full Text] [Related]
37. Characterization of immune response in Cross-Reactive Immunological Material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy.
Desai AK; Kazi ZB; Bali DS; Kishnani PS
Mol Genet Metab Rep; 2019 Sep; 20():100475. PubMed ID: 31193175
[TBL] [Abstract][Full Text] [Related]
38. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk.
Van den Hout JM; Kamphoven JH; Winkel LP; Arts WF; De Klerk JB; Loonen MC; Vulto AG; Cromme-Dijkhuis A; Weisglas-Kuperus N; Hop W; Van Hirtum H; Van Diggelen OP; Boer M; Kroos MA; Van Doorn PA; Van der Voort E; Sibbles B; Van Corven EJ; Brakenhoff JP; Van Hove J; Smeitink JA; de Jong G; Reuser AJ; Van der Ploeg AT
Pediatrics; 2004 May; 113(5):e448-57. PubMed ID: 15121988
[TBL] [Abstract][Full Text] [Related]
39. Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years.
Angelini C; Semplicini C; Ravaglia S; Bembi B; Servidei S; Pegoraro E; Moggio M; Filosto M; Sette E; Crescimanno G; Tonin P; Parini R; Morandi L; Marrosu G; Greco G; Musumeci O; Di Iorio G; Siciliano G; Donati MA; Carubbi F; Ermani M; Mongini T; Toscano A;
J Neurol; 2012 May; 259(5):952-8. PubMed ID: 22081099
[TBL] [Abstract][Full Text] [Related]
40. First successful concomitant therapy of immune tolerance induction therapy and desensitization in a CRIM-negative infantile Pompe patient.
Emecen Sanli M; Ertoy Karagol HI; Kilic A; Aktasoglu E; Inci A; Okur I; Ezgu F; Tumer L
J Pediatr Endocrinol Metab; 2022 Feb; 35(2):273-277. PubMed ID: 34561975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
